A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China
Latest Information Update: 30 Oct 2023
At a glance
- Drugs CB06-036 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shanghai Zhimeng Biopharma
Most Recent Events
- 30 Oct 2023 New trial record